Nucleolin is widely targeted for intracellular drug delivery, and this newly identified mechanism for its downregulation may shed further light on the role of this protein in cancer development, particularly considering the hypoxic nature of many solid tumors. This evidence concerns the gene NUCLEOLIN and cancer.